Last week, some things happened that made people change how they think about money and businesses. Because of this, some special groups of stocks did really well. I will tell you the three best ones.

The first one is a group of stocks about medicine and science. They did well because interest rates went down, which means it's cheaper for people to borrow money. This helps businesses that make new things like drugs.

The second one is a group of stocks about cars that use electricity instead of gas. These did well because many people are buying them and the companies that make them are doing great. They also work with technology companies to make their cars smarter.

The third one is a group of stocks about Apple, which is a big company that makes iPhones and other things. They did well because they made more money than people expected and said they will give some of it back to the people who own their stock. Read from source...

- The author does not provide any evidence or data to support the claim that corporate earnings have been bullish with Apple and Amazon beating expectations. This is a subjective opinion without factual basis.
- The author uses vague terms like "importance of AI growth" and "investments" without explaining how they are measured, what indicators or benchmarks are used to assess them, or how they impact the market performance. This is an unscientific statement that lacks rigor and clarity.
- The author mentions crude oil ETF dropping about 6.2% last week but does not provide any context or reason for this decline. Why did oil demand fall? What were the factors behind lower supply worries? How do these affect the economy and inflation? These are important questions that the author should have addressed to give a complete picture of the market dynamics.
- The author focuses on only three ETFs as examples of winning leveraged ETFs of last week, without comparing them with other alternatives or providing any performance analysis. This is a selective and biased presentation of information that does not reflect the diversity and complexity of the ETF landscape.

1. Direxion Daily S&P Biotech Bull 3x Shares (NYSEARC:LABU): This ETF is designed to provide 300% leveraged exposure to the daily performance of the S&P Biotechnology Index, which tracks the stocks of companies in the biotechnology industry. LABU has been one of the best-performing ETFs last week, as the U.S. benchmark treasury yield fell sharply, boosting growth stocks and biotech technology. Novel drug launches, likely low rates and potential easy access to funds should continue to support the sector in the near term. However, LABU is highly volatile and subject to significant price swings due to its leveraged nature and dependence on a single industry. Investors should monitor the developments in the biotech sector, especially regarding regulatory approvals, clinical trials, mergers and acquisitions, and market trends. LABU may not be suitable for risk-averse investors or long-term portfolios.

2